According to
Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best general drug manufacturer stocks to buy right now are:
1. Johnson & Johnson (NYSE:JNJ)
Johnson & Johnson (NYSE:JNJ) is the #1 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year.
Learn more.
The Component Grade breakdown for Johnson & Johnson (NYSE:JNJ) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: A, Financials: B, and AI: B.
Johnson & Johnson (NYSE:JNJ) has a Due Diligence Score of 53, which is 13 points higher than the general drug manufacturer industry average of 40.
JNJ passed 19 out of 38 due diligence checks and has strong fundamentals. Johnson & Johnson has seen its stock return 8.11% over the past year, overperforming other general drug manufacturer stocks by 5 percentage points.
Johnson & Johnson has an average 1 year
price target of $168.08, an upside of 7.53% from Johnson & Johnson's current stock price of $156.31.
Johnson & Johnson stock has a consensus Buy recommendation according to Wall Street analysts. Of the 12 analysts covering Johnson & Johnson, 16.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 50% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
2. Gilead Sciences (NASDAQ:GILD)
Gilead Sciences (NASDAQ:GILD) is the #2 top general drug manufacturer stock out of 18 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year.
Learn more.
The Component Grade breakdown for Gilead Sciences (NASDAQ:GILD) is: Value: B, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: B.
Gilead Sciences (NASDAQ:GILD) has a Due Diligence Score of 37, which is -3 points lower than the general drug manufacturer industry average of 40. Although this number is below the industry average, our proven quant model rates GILD as a "A".
GILD passed 13 out of 38 due diligence checks and has average fundamentals. Gilead Sciences has seen its stock return 63.4% over the past year, overperforming other general drug manufacturer stocks by 60 percentage points.
Gilead Sciences has an average 1 year
price target of $112.11, an upside of 5.22% from Gilead Sciences's current stock price of $106.54.
Gilead Sciences stock has a consensus Buy recommendation according to Wall Street analysts. Of the 19 analysts covering Gilead Sciences, 42.11% have issued a Strong Buy rating, 26.32% have issued a Buy, 31.58% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.
3. Bristol Myers Squibb Co (NYSE:BMY)
The Component Grade breakdown for Bristol Myers Squibb Co (NYSE:BMY) is: Value: A, Growth: C, Momentum: C, Sentiment: B, Safety: B, Financials: B, and AI: B.
Bristol Myers Squibb Co (NYSE:BMY) has a Due Diligence Score of 50, which is 10 points higher than the general drug manufacturer industry average of 40.
BMY passed 18 out of 38 due diligence checks and has strong fundamentals. Bristol Myers Squibb Co has seen its stock return 14.25% over the past year, overperforming other general drug manufacturer stocks by 11 percentage points.
Bristol Myers Squibb Co has an average 1 year
price target of $60.00, an upside of 19.52% from Bristol Myers Squibb Co's current stock price of $50.20.
Bristol Myers Squibb Co stock has a consensus Hold recommendation according to Wall Street analysts. Of the 13 analysts covering Bristol Myers Squibb Co, 23.08% have issued a Strong Buy rating, 7.69% have issued a Buy, 61.54% have issued a hold, while 0% have issued a Sell rating, and 7.69% have issued a Strong Sell.
